Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04069143 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04069143 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 14 participants.
The verdict
NCT04069143, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participants and participants with idiopathic pulmonary fibrosis (IPF).
Interventions
- DIAGNOSTIC_TEST 18F-BMS-986327
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04069143
The ClinicalTrials.gov registry entry for NCT04069143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-BMS-986327 is the first listed.
NCT04069143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04069143 about?
NCT04069143 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327". The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participants and participants with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT04069143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-10-01. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT04069143?
The interventions under investigation include: 18F-BMS-986327 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04069143?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.